Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mantle cell lymphoma
Pharma
An Imbruvica combo regimen could have a new future in MCL
AbbVie is making the case for its Johnson & Johnson-partnered BTK inhibitor Imbruvica to stage a comeback in mantle cell lymphoma.
Fraiser Kansteiner
Dec 12, 2023 12:33pm
Abbvie, J&J pull 2 Imbruvica accelerated approvals
Apr 7, 2023 10:25am
Lilly wins FDA approval for 4th BTK blood cancer drug
Jan 27, 2023 3:50pm
NICE signs off on BeiGene's Brukinsa for blood cancer disorder
Sep 20, 2022 10:10am
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Aug 25, 2022 9:37am
ASCO: Will lack of lymphoma survival win matter for Imbruvica?
Jun 3, 2022 8:00am